This week Dr. Durie answers the question "How does the new flow cytometry testing for MRD compare to molecular testing?"

 


Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

 

Previous Post
#AskDrDurie: Are clinical trials part of the BSRI(R), and if so, how can I participate?
Next Post
China update: renewed friendships and new collaborations

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.